Apogenix’s asunercept treatment has shown statistically significant benefits for hospitalised COVID-19 patients in its Asunctis trial.
Apogenix Receives €20.7 Million in Public Funding for Pivotal Study and Preparation for Market Production of Asunercept for the Treatment of COVID-19
A phase II clinical trial of a treatment for COVID-19 patients is currently starting at the Medical University of Vienna as a of the Austrian CoronaVirus Adaptive sub-study Clinical Trial (ACOVACT).
A phase II clinical trial of a treatment for COVID-19 patients is currently starting at the Medical University of Vienna as a of the Austrian CoronaVirus Adaptive sub-study Clinical Trial (ACOVACT).
Apogenix Advances Clinical Development of CD95L Inhibitor Asunercept in European COVID-19 Phase II TrialnnHeidelberg, Germany, October 13, 2020 - Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that the first patient has been enrolled in the ASUNCTIS trial. The ASUNCTIS trial is a multi-center, randomized, controlled, open-label phase II trial to assess the efficacy and safety of asunercept in patients with severe COVID-19 disease. In four treatment arms, three different doses of asunercept plus standard of care versus standard of care alone are being evaluated in a total of 400 patients. Apogenix has received regulatory approval for the ASUNCTIS trial now in both Spain and Russia and will enroll patients in multiple study centers in Madrid and Saint Petersburg, among others.